Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.

2023-04

Cox, Daniel R A

Chung, William

Grace, Josephine A

Wong, Darren

Kutaiba, Numan

Ranatunga, Dinesh G

Khor, Richard

Perini, Marcos V

Fink, Michael A

Jones, Robert M

Goodwin, Mark D

Dobrovic, Alex

Testro, Adam G

Muralidharan, Vijayaragavan

alpha‐fetoprotein

des‐γ‐carboxyprothrombin

hepatocellular carcinoma

lens culinaris agglutinin‐A‐reactive α‐fetoprotein

loco‐regional therapy

microwave ablation

protein induced by vitamin K absence or antagonist‐II

radiofrequency ablation

trans‐arterial chemo‐embolization

α‐fetoprotein

Journal Article

0000-0002-5092-4370

0000-0002-8624-318X

0000-0002-8435-4740

0000-0003-1490-0547

0000-0003-4627-9847

#PLACEHOLDER_PARENT_METADATA_VALUE#

0000-0002-7057-2747

0000-0002-0165-1564

0000-0002-9684-4691

0000-0002-8415-5565

0000-0002-1476-0591

0000-0003-3414-112X

0000-0001-6776-3115

0000-0001-8247-8937

10.1002/jgh3.12879

Hepatocellular carcinoma (HCC) is an aggressive primary malignancy of the liver and is the third most common cause of cancer-related global mortality. There has been a steady increase in treatment options for HCC in recent years, including innovations in both curative and non-curative therapies. These advances have brought new challenges and necessary improvements in strategies of disease monitoring, to allow early detection of HCC recurrence. Current serological and radiological strategies for post-treatment monitoring and prognostication and their limitations will be discussed and evaluated in this review.

link

JGH Open : an Open Access Journal of Gastroenterology and Hepatology 2023; 7(4)

JGH Open : an Open Access Journal of Gastroenterology and Hepatology

2397-9070